Preferred Label : Pembrolizumab/Quavonlimab MK-1308A;
NCIt synonyms : Quavonlimab/Pembrolizumab MK-1308A; Pembrolizumab/Quavonlimab Formulation MK-1308A; Pembrolizumab/Quavonlimab; Pembrolizumab-Quavonlimab; Antibodies Combination Formulation MK-1308A;
NCIt definition : A combination formulation containing fixed doses of the two monoclonal antibodies
pembrolizumab and quavonlimab, with potential immune checkpoint inhibitory and antineoplastic
activities. Upon administration of pembrolizumab/quavonlimab MK-1308A, pembrolizumab,
a monoclonal antibody directed against the human cell surface receptor PD-1 (programmed
death-1 or programmed cell death-1), targets and binds to PD-1, an inhibitory signaling
receptor expressed on the surface of activated T cells, and blocks the binding to
and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated
immune responses against tumor cells. The ligands for PD-1 include programmed cell
death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell
death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs).
Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor
evasion from host immunity. Quavonlimab, a monoclonal antibody directed against the
human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4;
CTLA-4), targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated
downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated
immune response against cancer cells. CTLA4, an inhibitory receptor and member of
the immunoglobulin superfamily, plays a key role in the downregulation of the immune
system.;
Molecule name : MK 1308A; MK-1308A;
Origin ID : C200832;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
